RLMD logo

Relmada Therapeutics (RLMD) Selling, General & Administrative Expenses

Annual SGA

$48.89 M
+$968.80 K+2.02%

December 31, 2023


Summary


Performance

RLMD SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRLMDexpensesmetrics:

Quarterly SGA

$11.86 M
+$3.76 M+46.46%

September 30, 2024


Summary


Performance

RLMD Quarterly SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRLMDexpensesmetrics:

TTM SGA

-$2.37 B
-$86.49 M-3.79%

September 30, 2024


Summary


Performance

RLMD TTM SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRLMDexpensesmetrics:

Selling, General & Administrative Expenses Formula

SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development

RLMD Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+2.0%+22.5%-5212.6%
3 y3 years+96.6%+37.0%-7450.6%
5 y5 years+757.3%+551.6%-10000.0%

RLMD Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+39.4%-18.8%+46.5%-135.4%at low
5 y5-yearat high+927.6%-18.8%+551.6%-561.9%at low
alltimeall timeat high>+9999.0%-18.8%>+9999.0%<-9999.0%at low

Relmada Therapeutics Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sep 2024
-
$11.86 M(+46.5%)
$41.72 M(-0.9%)
Jun 2024
-
$8.10 M(-16.4%)
$42.10 M(-9.1%)
Mar 2024
-
$9.68 M(-19.8%)
$46.28 M(-5.3%)
Dec 2023
$48.89 M(+2.0%)
$12.08 M(-1.3%)
$48.90 M(+0.5%)
Sep 2023
-
$12.24 M(-0.4%)
$48.65 M(+9.0%)
Jun 2023
-
$12.29 M(-0.0%)
$44.62 M(-4.9%)
Mar 2023
-
$12.29 M(+3.9%)
$46.93 M(-2.1%)
Dec 2022
$47.93 M(+36.6%)
$11.83 M(+44.2%)
$47.93 M(+6.5%)
Sep 2022
-
$8.21 M(-43.8%)
$45.00 M(-1.0%)
Jun 2022
-
$14.60 M(+9.9%)
$45.45 M(+13.7%)
Mar 2022
-
$13.28 M(+49.1%)
$39.98 M(+14.0%)
Dec 2021
$35.08 M(+41.1%)
$8.91 M(+2.9%)
$35.08 M(+9.0%)
Sep 2021
-
$8.66 M(-5.2%)
$32.19 M(+9.2%)
Jun 2021
-
$9.13 M(+8.9%)
$29.48 M(+6.1%)
Mar 2021
-
$8.38 M(+39.3%)
$27.78 M(+11.7%)
Dec 2020
$24.87 M(+422.6%)
$6.02 M(+1.2%)
$24.87 M(+31.9%)
Sep 2020
-
$5.95 M(-20.0%)
$18.85 M(+28.0%)
Jun 2020
-
$7.43 M(+36.0%)
$14.72 M(+76.2%)
Mar 2020
-
$5.47 M(+200.4%)
$8.35 M(+27.8%)
Dec 2019
$4.76 M(-16.6%)
-
-
Sep 2019
-
$1.82 M(+70.8%)
$6.53 M(+14.6%)
Jun 2019
$5.70 M(+43.5%)
$1.07 M(-25.3%)
$5.70 M(+1.7%)
Mar 2019
-
$1.43 M(-35.8%)
$5.61 M(+10.7%)
Dec 2018
-
$2.22 M(+124.5%)
$5.07 M(+22.1%)
Sep 2018
-
$989.70 K(+1.9%)
$4.15 M(+4.4%)
DateAnnualQuarterlyTTM
Jun 2018
$3.97 M(-32.9%)
$970.90 K(+10.0%)
$3.97 M(-13.6%)
Mar 2018
-
$883.00 K(-32.4%)
$4.60 M(-16.5%)
Dec 2017
-
$1.31 M(+60.2%)
$5.51 M(+0.4%)
Sep 2017
-
$815.10 K(-49.0%)
$5.49 M(-7.4%)
Jun 2017
$5.93 M(-40.8%)
$1.60 M(-10.8%)
$5.93 M(-13.1%)
Mar 2017
-
$1.79 M(+39.8%)
$6.82 M(-4.8%)
Dec 2016
-
$1.28 M(+2.4%)
$7.16 M(-24.5%)
Sep 2016
-
$1.25 M(-49.7%)
$9.48 M(-5.1%)
Jun 2016
$10.01 M(+8.5%)
$2.49 M(+16.4%)
$9.99 M(+10.5%)
Mar 2016
-
$2.14 M(-40.7%)
$9.04 M(-1.8%)
Dec 2015
-
$3.60 M(+104.3%)
$9.21 M(+16.6%)
Sep 2015
-
$1.76 M(+14.7%)
$7.90 M(-13.6%)
Jun 2015
$9.23 M(-23.8%)
$1.54 M(-33.2%)
$9.14 M(+20.2%)
Mar 2015
-
$2.30 M(+0.4%)
$7.60 M(+43.4%)
Dec 2014
-
$2.29 M(-23.6%)
$5.30 M(+75.4%)
Sep 2014
-
$3.00 M(>+9900.0%)
$3.02 M(+5966.7%)
Jun 2014
$12.11 M(>+9900.0%)
-
-
Feb 2014
-
$3100.00(-78.6%)
$49.80 K(-2.9%)
Nov 2013
-
$14.50 K(+16.9%)
$51.30 K(+11.3%)
Aug 2013
$46.10 K(+234.1%)
$12.40 K(-37.4%)
$46.10 K(+7.7%)
May 2013
-
$19.80 K(+330.4%)
$42.80 K(+67.2%)
Feb 2013
-
$4600.00(-50.5%)
$25.60 K(+13.3%)
Nov 2012
-
$9300.00(+2.2%)
$22.60 K(+69.9%)
Aug 2012
$13.80 K
$9100.00(+250.0%)
$13.30 K(+216.7%)
May 2012
-
$2600.00(+62.5%)
$4200.00(+162.5%)
Feb 2012
-
$1600.00
$1600.00

FAQ

  • What is Relmada Therapeutics annual SGA?
  • What is the all time high annual SGA for Relmada Therapeutics?
  • What is Relmada Therapeutics annual SGA year-on-year change?
  • What is Relmada Therapeutics quarterly SGA?
  • What is the all time high quarterly SGA for Relmada Therapeutics?
  • What is Relmada Therapeutics quarterly SGA year-on-year change?
  • What is Relmada Therapeutics TTM SGA?
  • What is the all time high TTM SGA for Relmada Therapeutics?
  • What is Relmada Therapeutics TTM SGA year-on-year change?

What is Relmada Therapeutics annual SGA?

The current annual SGA of RLMD is $48.89 M

What is the all time high annual SGA for Relmada Therapeutics?

Relmada Therapeutics all-time high annual SGA is $48.89 M

What is Relmada Therapeutics annual SGA year-on-year change?

Over the past year, RLMD annual SGA has changed by +$968.80 K (+2.02%)

What is Relmada Therapeutics quarterly SGA?

The current quarterly SGA of RLMD is $11.86 M

What is the all time high quarterly SGA for Relmada Therapeutics?

Relmada Therapeutics all-time high quarterly SGA is $14.60 M

What is Relmada Therapeutics quarterly SGA year-on-year change?

Over the past year, RLMD quarterly SGA has changed by +$2.18 M (+22.48%)

What is Relmada Therapeutics TTM SGA?

The current TTM SGA of RLMD is -$2.37 B

What is the all time high TTM SGA for Relmada Therapeutics?

Relmada Therapeutics all-time high TTM SGA is -$12.10 K

What is Relmada Therapeutics TTM SGA year-on-year change?

Over the past year, RLMD TTM SGA has changed by -$2.41 B (-5212.58%)